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ABSTRACT
Introduction: BIW-8962 is a monoclonal
antibody to GM2 ganglioside that shows
preclinical activity towards multiple myeloma
(MM) cell lines and in animal models bearing
MM xenografts. The objective of this study was
to determine the safety, tolerability, maximum
tolerated dose (MTD), pharmacokinetics,
potential immunogenicity, and preliminary
clinical efficacy of BIW-8962 in patients with
heavily pretreated MM.
Methods: Patients (n = 23) received escalating
doses of BIW-8962 (0.03–3 mg/kg)
intravenously every 2 weeks in phase Ia. The
highest anticipated dose (10 mg/kg) was not
tested and the study was discontinued without
proceeding to phases Ib and II.
Results: The MTD of BIW-8962 was not
established and BIW-8962 was relatively well
tolerated. No pattern of consistent toxicity
could be inferred from treatment-related AEs
grade C3 and only two dose-limiting toxicities
were recorded (atrial
thrombosis ? cardiomyopathy and chest pain,
respectively). In the efficacy evaluable
population (n = 22), no patient had a response
(complete or partial) and 16 (72.7%) had a best
response of stable disease, which was generally
not durable.
Conclusion: BIW-8962 did not show evidence
of clinical activity. The study was therefore
stopped and further development of BIW-8962
in MM was halted.
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article go to http://www.medengine.com/Redeem/
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INTRODUCTION
Multiple myeloma (MM) is a B cell malignancy
characterized by abnormal monoclonal
expansion of plasma cells, usually
accompanied by a monoclonal protein
(myeloma-protein; M-protein) found in the
blood and/or urine. Clinical features include
renal failure, anemia, recurrent infections,
skeletal destruction, and hypercalcemia [1].
MM accounts for around 18% of
hematological malignancies, resulting in an
estimated 30,330 new cancer cases and
12,650 deaths in the USA for 2016 [2].
Advances in the treatment of
newly-diagnosed MM over recent decades,
including high-dose chemotherapy with
autologous stem cell transplantation,
immunomodulatory drugs (e.g., thalidomide,
lenalidomide), and proteasome inhibitors (e.g.,
bortezomib) have improved clinical outcome
[3, 4]. This is reflected in the significant
improvement in 5-year relative survival rate
in the USA from 25% in 1975–1977 to 49% in
2005–2011 [2]. Virtually all MM patients
ultimately relapse or become refractory after
first- or second-line therapy [5] and these
patients represent a clinical challenge because
of their poor clinical outcome [6]. Alternative
immunomodulatory drugs (pomalidomide) [7]
and proteasome inhibitors (carfilzomib,
ixazomib) [8, 9], new agents such as the
histone deacetylase inhibitor panobinostat
[10], and novel monoclonal antibodies
(mAbs) directed at different targets such as
CD38 (daratumumab) [11] and SLAMF7
(elotuzumab) [12] have been approved more
recently for treatment of relapsed/refractory
MM. Novel agents that act through different
mechanisms are still needed and are under
investigation [13].
Gangliosides are ubiquitous cell membrane
components composed of a carbohydrate chain
with sialic acid at the cell surface and a
hydrophobic ceramide in the lipid bilayers
[14]. Some of these gangliosides play a role in
cell–cell recognition [15] and cell–matrix
attachment [16] that regulate cell growth and
differentiation [17, 18]. Quantitative and
qualitative changes are known to occur in the
expression of gangliosides through the
oncogenic transformation of cells [15], so
attention has been directed to gangliosides as
therapeutic targets [19, 20]. The recognition of
potential immunologic differences between
cancer cells and normal cells led to an
immunotherapy trial in an attempt to
immunize metastatic melanoma patients
against the GM2 ganglioside [21]. GM2
ganglioside is expressed in a range of other
tumor cell types, e.g. neuroblastoma, leukemia,
and it was noted that the majority of myeloma
cell lines (70%) and myeloma cells in patient
marrow specimens (64%) expressed GM2
ganglioside on the cell surface [22].
BIW-8962 is a recombinant, humanized,
non-fucosylated immunoglobulin G1 mAb
directed against the GM2 ganglioside.
BIW-8962 was produced in Chinese Hamster
Ovary (CHO) cells that lack the FUT8 gene,
rendering the mAb devoid of fucose in the
carbohydrate structure. Non-fucosylated mAbs
have been shown to have up to 100-fold higher
antibody-dependent cell-mediated cytotoxicity
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(ADCC) against tumor cells compared to
conventional fucosylated antibodies [23].
Preclinical studies employed a precursor mAb,
KM8969, with the same
complementarity-determining regions as
BIW-8962. The binding activity of KM8969
was assessed with an enzyme-linked
immunoassay using various immobilized
gangliosides as previously reported [24].
KM8969 reacted strongly with N-acetyl-GM2
and N-glycolyl-GM2 but weakly with GD2.
In vitro preclinical studies (data on file, Kyowa
Kirin Pharmaceutical Development, Inc.)
showed that KM8969 bound to many MM cell
lines in flow cytometric analysis and exhibited
potent ADCC and complement-mediated
cytotoxicity towards MM cell lines. In vivo,
KM8969 effected dose-dependent antitumor
activity that plateaued at 3–10 mg/kg in the
KMS-11 human MM xenograft severe combined
immunodeficiency mouse model after
intravenous (iv) administration twice weekly
for 3 weeks.
The aim of the current first-in-human phase I
study was to determine the safety, tolerability,
maximum tolerated dose (MTD),
pharmacokinetics, potential immunogenicity,
and preliminary clinical efficacy of BIW-8962
administered by iv infusion as monotherapy in




The primary phase I objective was to establish
the safety profile and recommended phase II
dose as determined by either the MTD or the
active biologic dose (ABD) of BIW-8962 in
patients with previously treated MM.
Secondary objectives were to determine the
pharmacokinetic profile of BIW-8962, to
evaluate preliminary evidence of antitumor
activity, and to screen for potential antibodies
against BIW-8962.
As this was the first-in-class human study of
BIW-8962, the starting dose level was based on a
12-week toxicology study in cynomolgus
monkeys (data on file, Kyowa Kirin
Development, Inc.), which showed the no
observed adverse effect level was 0.1 mg/kg
administered weekly. The selected human
starting dose of BIW-8962 0.03 mg/kg iv once
every 2 weeks provided a safety factor of six
with the dosing regimen difference factored in,
which is sufficiently high for relapsed MM
patients.
The study had a multi-center, open-label
design consisting of three sequential parts: dose
escalation to determine the MTD or ABD (phase
Ia) followed by dosing regimen determination
using adjustment with a loading dose (phase Ib)
followed by an efficacy assessment (phase II).
Phases Ib and II were not conducted due to lack
of preliminary efficacy in phase Ia and, as such,
are not described herein. Phase Ia employed a
standard 3 ? 3 dose-escalation design.
Increasing doses of BIW-8962 (0.03, 0.1, 0.3, 1,
3, and 10 mg/kg) were administered every
2 weeks. Patients not receiving at least two full
doses of BIW-8962 in a dose cohort were
replaced, except for those who experienced
BIW-8962-related toxicity.
BIW-8962 was administered by iv infusion in
0.9% saline (25–250 ml depending on dose
level) over 60 min, except the 0.03 mg/kg dose
which was delivered over 15–20 min. All
infusions were delivered with an infusion
pump through a 0.22-lm protein-sparing/
low-protein-binding in-line filter. Routine
premedication for the prophylaxis of infusion
reactions was not allowed. Patients were
allowed to continue treatment until disease
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progression, unacceptable toxicity, grade 3/4
infusion reactions, or any event that required
[2 dose reductions.
Dose-limiting toxicity (DLT) was defined as
any grade C3 hematologic or non-hematologic
toxicity that was considered by the investigator
to be probably or possibly related to BIW-8962.
Patients who experienced grade 3 nausea,
vomiting, or diarrhea were not considered as
DLT if they could be managed and reduced to
grade B1 within 24 h and, in subsequent
courses, when subjects are given appropriate
prophylaxis, they do not recur at grade[2.
Patients
Eligible patients included adults (C18 years)
with ECOG performance status B2 and
adequate hematological and organ function
who presented measurable, symptomatic MM
documented by IMWG criteria [1] who had
failed C2 prior MM therapies. Full inclusion/
exclusion criteria are detailed as supplementary
material (available online).
Safety and Clinical Assessment
Demographic and medical/cancer histories were
recorded at screening. Bone marrow aspiration
and biopsy were performed during screening.
Physical examination and laboratory value
assessments were undertaken at screening, on
day 1 of each course (every 2 weeks), at the end
of treatment, and at follow up. Vital signs were
recorded at all visits. ECG was undertaken at
screening, post-infusion on day 1 of each
course, and at end of treatment. Serum and
urinary M protein and free light chain analyses
were performed at screening, on day 1 of course
1 and on day 1 of every other course, and at
study termination. Fluorescence-activated cell
sorting analysis was performed on T, B and NK
cells at screening and prior to each treatment
course. Immunogenicity samples were taken at
screening, immediately before doses 3 and 4,
and 8 weeks after the last dose using an
enzyme-linked immunosorbent assay for
detection of human antibodies to BIW-8962.
All patients were followed after the last dose
until confirmation of progression or start of
alternative treatment.
Adverse events (AEs) were recorded following
observations by the investigator during clinic
visits or in response to non-leading questions,
spontaneous reporting by the patient, or on the
basis of clinical or laboratory tests. They were
graded by National Cancer Institute Common
Terminology Criteria for Adverse Events
(NCI-CTCAE) v 3.0. and classified by the
investigator with respect to relationship to
treatment with BIW-8962 (definitely, probably,
possibly, unlikely, or unrelated).
Treatment-related AEs included those
considered definitely, probably, or possibly
related to BIW-8962. The safety analysis
population included all patients who received
at least one dose of BIW-8962. Serious AEs
(SAEs) were reported in an expedited manner.
Response Assessment
Best overall response was determined in the
efficacy evaluable population, which included
those patients with baseline and at least one
on-study assessment for response. Confirmation
of response required two consecutive
assessments. Response was assessed by IMWG
criteria every 4 weeks. Response assessment
included quantitation of M-protein (serum and
urine), urinary Bence-Jones protein for patients
who do not have complete monoclonal
immunoglobulins, or, in the absence of
M-protein detectable by either electrophoresis
or immunofixation, free light chain (FLC)
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analysis. As clinically appropriate, response
assessment may also include bone marrow
analysis and imaging of plasmacytoma.
Samples for M-protein (serum and urine) and
FLC analyses (serum and urine) were analyzed
at a central laboratory (ICON Laboratories,
Farmingdale, NY).
Pharmacokinetics
Blood samples were taken pre-dose, and at 0
(end of infusion) 1, 2, 4, 6, 24, 72, 96, 168, 216,
and 336 h following the first dose of BIW-8962.
After the second dose of BIW-8962, blood
samples were taken pre-dose, and at 0, 24, 96,
216, and 336 h. Plasma samples were analyzed
at a central laboratory (Tandem, Inc., West
Trenton, NJ) using a validated sandwich
electrochemiluminescence assay. The
quantification range was 80–5120 ng/ml.
Pharmacokinetic parameters including area
under the plasma concentration–time curve
from time zero to the time of the last
measurable concentration (AUClast) and to
infinity (AUC?), maximum plasma
concentration (Cmax), time to Cmax (Tmax),
total systemic clearance (CL), volume of
distribution in the terminal phase (Vz), and
elimination half-life (t1/2) were calculated using
non-compartmental methods with WinNonLin
version 5.0 software (Pharsight A Certara
Company, Mountain View, CA).
Statistics
Safety, efficacy, and pharmacokinetics were
summarized by descriptive statistics.
Compliance with Ethical Guidelines
The study was conducted in accordance with
the Declaration of Helsinki and International
Conference for Harmonization of Good Clinical
Practice Guidelines. The protocol and its
subsequent amendments were approved by the
Institutional Review Board at each of the four
study centers (H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL; Barbara Ann
Karmanos Cancer Institute, Detroit, MI;
Cleveland Clinic Foundation, Cleveland, OH;
Duke University Medical Center, Durham, NC).
The study was registered in ClinicalTrials.gov
(NCT00775502). All patients provided written
informed consent prior to study registration.
RESULTS
Patient Characteristics
The study is complete and was conducted
between 13 February 2009 and 30 November
2010. The baseline clinical and demographic
characteristics of the patients are summarized in
Table 1. All patients had received at least 3 prior
systemic therapies and 83% had received [4
prior systemic therapies for treatment of
myeloma. All patients had received prior
bortezomib and corticosteroids, and all but
one had received prior lenalidomide. The
patients had also received many other
standard and investigational therapies, as well
as stem cell transplantation.
Patient disposition and drug exposure are
summarized in Table 2. The safety and efficacy
populations included 23 and 22 patients,
respectively. The reasons for discontinuation
from the study were progressive disease (n = 22,
95.7%) and AEs (n = 1, 4.3%).
Dose-Limiting Toxicity
Two patients developed DLTs: one at 0.03 mg/
kg and one at 1 mg/kg. The number of evaluable
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patients was therefore increased to six in each of
these cohorts. Seven patients eventually entered
the 0.03 mg/kg cohort as one patient received
only one dose and discontinued study
medication due to disease progression, which
necessitated replacement. No additional
patients developed DLT. The DLT in the
0.03 mg/kg cohort was grade 3 atrial
thrombosis and cardiomyopathy possibly
related to the study drug. The DLT in the
1 mg/kg cohort was grade 3 chest pain
probably related to the study drug. The latter
patient died during the study but this was not
considered drug-related (see next section). Both
DLTs led to discontinuation of study drug.
Neither the MTD nor the ABD was reached.
No patients were recruited to the highest
planned dose level of 10 mg/kg prior to
discontinuation of the trial.
Safety
AEs are summarized in Table 3.
Treatment-related AEs occurred in 8 (34.8%)
patients, did not appear related to dose, and, by
preferred term, were reported in individual
patients except for alopecia (n = 2). There were
no treatment-related life-threatening AEs or
deaths. Treatment-related grade 3 AEs were
reported in two patients (atrial
thrombosis ? cardiomyopathy in one patient
and chest pain in the other): these were the
DLTs reported above. The patient who
experienced grade 3 chest pain probably
related to BIW-8962 occurred after receiving a
partial dose of study drug (1 mg/kg cohort) on
day 1 in the context of a grade 2 infusion
reaction: the patient died on day 6 due to
cardiopulmonary arrest that was considered
unrelated to the study drug. The patient who
experienced grade 3 atrial thrombosis and
cardiomyopathy had a medical history of
congestive heart failure with pre-existing
cardiomyopathy. Both these DLTs were classed
as SAEs. One other patient experienced a
treatment-related SAE: this involved a patient
who received 3 mg/kg and experienced grade 3
fatigue plus a grade 2 infusion reaction, which
Table 1 Baseline clinical and demographic characteristics
Characteristic Total (n5 23)






African American 6 (26.1)









Median (min–max) 6 (3–28)




Light chain kappa 1 (4.3)
Light chain lambda 5 (21.7)
Not recorded 1 (4.3)
Percentages may not equal 100% exactly due to rounding
ECOG Eastern Cooperative Oncology Group, MM
multiple myeloma
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were considered probably and definitely related
to study drug, respectively. All other SAEs were
not considered related to the study drug and
were generally typical of the underlying disease
process, e.g. hypercalcemia, plasmacytoma,
infection, fracture.
No unexpected trends or safety concerns
were identified from laboratory parameter, vital
sign, or ECG assessments. Anti-BIW-8962
antibodies were not detected in plasma for any
patients except one who developed a weakly
positive response.
Anti-Tumor Activity
No patient had a complete or partial response,
with no patient showing a C50% reduction in
serum M protein and a C90% reduction in 24-h
urinary M protein or to\200 mg/24 h. Sixteen
of 22 evaluable patients (72.7%) had
stable disease (SD). The longest duration of SD
was *9 months in a patient who received
BIW-8962 0.3 mg/kg (Fig. 1). This patient was
diagnosed in 2003 and received four cycles of
vincristine, doxorubicin, and dexamethasone,
and then underwent high-dose chemotherapy
and stem cell transplantation in November
2003. Remission lasted for 2 years until March
2006. She then received six cycles of bortezomib
with a response and was subsequently placed on
thalidomide maintenance therapy, which she
received intermittently until February 2008
when she again experienced progressive
disease. She then received four cycles of
bortezomib, lenalidomide, and dexamethasone
for 4 cycles and was then subsequently
maintained on lenalidomide. In December
2009, she experienced progressive disease and
entered the current trial of BIW-8962. Three
additional patients had SD for *3 months.
Median time to disease progression was 6.7
(range 2.1–34.1) weeks (Table 2).
Fig. 1 Response in the patient with sustained (*9 months) stable disease
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Pharmacokinetics
A summary of BIW-8962 pharmacokinetic
parameters following the administration of the
first and second dose of BIW-8962 every 2 weeks
is shown in Table 4. Cmax increased in a dose
proportional manner over the 0.03–3 mg/kg
dose range. Systemic exposure based on
AUClast and AUC? values increased in a dose
proportional up to 1 mg/kg but was greater than
the dose increase at 3 mg/kg. The ratio of
AUClast comparing the second and first dose of
BIW-8962 was *1.3 at 0.03–0.3 mg/kg doses
and *1.6 at 1 and 3 mg/kg doses. Mean t1/2
ranged from 80.2 to 266 h across the dose
cohorts and appeared longer after the second
dose, particularly at the higher doses of 1 and
3 mg/kg. Mean Vz ranged from 53.0 to 94.4 ml/
kg and did not appear dose related. Mean CL
ranged from 0.229 to 0.544 lg h/ml and may
have been slower at the highest dose of 3 mg/
kg.
DISCUSSION
Neither the MTD nor the ABD for BIW-8962
were determined in this first-in-class human
study of this monoclonal antibody to the
ganglioside GM2 in patients with heavily
pretreated MM. The study was stopped
prematurely during dose escalation in phase Ia
and the highest dose of BIW-8962 10 mg/kg was
not tested. The study was stopped because of
insufficient evidence of clinical activity and the
study did not progress to phase Ib or phase II as
initially planned.
BIW-8962 administered iv up to 3 mg/kg
twice weekly did not show any efficacy. None of
the 22 patients evaluable for efficacy showed a
response (complete or partial). Sixteen of 22
evaluable patients (72.7%) had SD. The longest
duration of SD was *9 months and three
additional patients had SD for *3 months, so
there was little evidence of patients achieving
durable SD.
The MTD was not reached. At the doses
tested, BIW-8962 was relatively well tolerated.
No pattern of consistent toxicity could be noted
from treatment-related AEs grade C3 and only
two DLTs were recorded during dose escalation.
Pharmacokinetic analysis showed that
BIW-8962 distribution appears primarily
confined to serum following iv administration.
It is eliminated slowly with a mean half-life
ranging from 80 to 266 h across the dose
cohorts. Systemic exposure increased in a
dose-related manner up to 1 mg/kg, although,
at 3 mg/kg, the increase in systemic exposure
was greater than the dose increase. Trough
levels of BIW-8962 were within the range
which would have been expected to cause
cytotoxicity if in vitro data against MM cell
lines and in the preclinical animal MM model
that showed activity for BIW-8962 were
extrapolated to patients.
The reason for the lack of clinical activity is
unknown. It may be that preclinical activity
in vitro and in vivo for BIW-8962 does not
translate in patients. Since the conclusion of
study and decision to discontinue the
development of BIW-8962, we have become
aware of studies with elotuzumab in MM
patients. Single-agent treatment with
elotuzumab showed no objective clinical
responses in a phase I study in heavily
pretreated MM patients [25]. Given that
lenalidomide and bortezomib enhanced the
activity of elotuzumab in preclinical models,
further clinical studies were conducted of
elotuzumab in combination lenalidomide
[26, 27] and bortezomib [28, 29] that
demonstrated additive or synergistic activities
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in MM patients. We have not investigated the
potential synergism of BIW-8962 with other
agents such as lenalidomide, bortezomib, or
carfilzomib and cannot therefore rule out this
possibility. Similarly, while nivolumab (an
anti-PD-1 mAb) was not associated with
single-agent activity in MM [30],
pembrolizumab (another anti-PD-1 mAb) in
combination with lenalidomide has
demonstrated responses in
lenalidomide-refractory MM patients [31]. As
opposed to elotuzumab, mAbs targeting CD38
(daratumamab, isatuximab, and MOR03087)
have shown evidence of single-agent activity
in patients with relapsed/refractory MM [32].
This was the basis for the approval of
daratumumab in the USA.
A limitation of our study, which may have
masked potential clinical activity of BIW-8962,
was that we were unable to determine the GM2
status of patients by flow cytometric analysis of
bone biopsy samples due to either limited
stability of GM2 or because the external
laboratory that performed the analysis did not
first enrich the samples for CD138? by use of a
preparatory column.
CONCLUSION
Further development of BIW-8962 in MM was
discontinued given the complete lack of clinical
efficacy.
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